Elvina Almuradova, Associate Professor, Medicana Health Group, shared a post on X:
“The NCT03886441 trial, where the addition of beclomethasone significantly reduced the rate of radiotherapy-induced pneumonia, delivered impressive results.
Interventions like this are simple, accessible, cost-effective, and can be easily implemented in clinics worldwide, offering a real improvement in patients’ quality of life.
Further phase III trials are essential.
– Reduced radiation pneumonitis: 35.3% vs. 52.8% (P=0.03)
– Severe cases dropped: 12% vs. 28.2% (P=0.01)
– No difference in overall survival
– Increased hyperglycemia in steroid group (P=0.025).”
Source: Elvina Almuradova/X